Strides Pharma Science Ltd
Strides Pharma Science Q3 FY26 Results & Concall Highlights
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Strides Pharma aims to achieve around $400 million revenue from the US market by FY'28, with growth expected over the next 9 quarters. The company aims to reach US revenues of $400 million by FY'28 with consistent growth expected over the next 2 years. - Operational PAT grew 65% in the 9-month period with an operational EPS of Rs.
From Strides Pharma Science Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Strides Pharma aims to achieve around $400 million revenue from the US market by FY'28, with growth expected over the next 9 quarters.
- Ex-US markets (other regulated and growth markets) are growing faster than anticipated, now contributing 47% of Q3 FY'26 revenues with 20% YoY growth; the gap between US and Ex-US revenues has significantly narrowed.
- Growth drivers include ramping up dormant products, control substances normalizing, investing in complex generics like nasal sprays and 505(b)(2) programs, and expanding product portfolios within existing geographies.
- The company foresees consistent growth rather than quarter-to-quarter spikes, with multiple levers in place across markets.
- Planned launches and portfolio expansions will sustain growth; the focus remains on profitability and EBITDA margin expansion.
- The regulatory pathway and customer base in Ex-US markets are mature, supporting steady growth.
- Industry-wide pricing pressure remains, but improved cost of goods sold helps maintain margins.
Profitability & Margins
See what Strides Pharma Science Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Maintenance CAPEX is on track in the range of Rs. 100 crore to Rs. 125 crore.
- Additional CAPEX includes opportunistic targeted purchases of global rights for both US and Ex-US markets, though no specific numbers are provided.
- Rs. 284 crores invested in CAPEX for tangible and intangible assets during the 9-month period.
- Investments are aimed at driving growth in both the US and Ex-US markets.
- The company plans to continue investing in R&D programs, expected to start delivering revenue in the next 12 to 18 months.
- Focus remains on balancing CAPEX between maintenance and growth opportunities without compromising on profitability.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Strides Pharma Science Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Order book in access market currently subdued due to reduced donor funding, especially from large institutions like the Global Fund.
- Several countries have lowered their contributions, causing a significant reduction in orders not only for Strides but industry-wide.
- Allocation periods are rolling over as donors have not fulfilled obligations.
- Some countries are increasing contributions to fill funding gaps caused by others, but the gap remains large.
- Near-term outlook for access market orders is muted.
- Expectation that donor funding and order volumes will improve or "ameliorate" gradually in the near future.
Strides Pharma Science Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.3K Cr, net profit ₹129 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Strides Pharma Science Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- OneSource Specialty Pharma Ltd (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
- Mankind Pharma Ltd (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
- Gland Pharma (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
- Shilpa Medicare Ltd (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…
Frequently Asked Questions
What were Strides Pharma Science Ltd Q3 FY26 results?
Strides Pharma aims to achieve around $400 million revenue from the US market by FY'28, with growth expected over the next 9 quarters. The company aims to reach US revenues of $400 million by FY'28 with consistent growth expected over the next 2 years. - Operational PAT grew 65% in the 9-month period with an operational EPS of Rs.
What is Strides Pharma Science Ltd share price analysis?
Strides Pharma Science Ltd currently shows a neutral. The stock trades at a P/E of 15.4 with a market cap of ₹8,944 Cr. Investors should review the full earnings analysis for detailed insights.
Is Strides Pharma Science Ltd planning capital expenditure?
Maintenance CAPEX is on track in the range of Rs.
Keep Strides Pharma Science Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.